Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Best Articles from British Journal of Dermatology
Description
The presentation highlighted significant findings from recent articles published in the British Journal of Dermatology (BJD) across various methodological sections. Key studies reviewed included a phase three trial on baricitinib for atopic dermatitis in children, showing efficacy at 4 mg with no safety concerns, and a major meta-analysis on cardiovascular safety in atopic dermatitis treatments, indicating no substantial adverse effects but highlighting the need for further real-world data. Additionally, a study on anifrolumab for treatment-resistant cutaneous lupus revealed promising results and insights into its mechanism of action. The exploration of baricitinib for alopecia areata noted varying response times depending on baseline severity, urging clinicians to manage patient expectations. An article addressing skin aging attracted wide media attention by linking perceived youthfulness to lower rates of age-related diseases. Furthermore, data from the UK psoriasis registry demonstrated superior efficacy and treatment persistence with adalimumab compared to methotrexate. Research into metformin's mechanisms in hidradenitis suppurativa revealed its anti-inflammatory effects. A global health initiative investigated the use of Ayurvedic methods to treat lymphatic filariasis, showcasing accessible interventions in resource-limited settings. Finally, the presentation emphasized the importance of standardized outcome measures in clinical trials and promoted the use of graphical abstracts to enhance understanding of complex studies. Overall, the BJD remains committed to global dermatological advancements and collaboration.
View moreConclusions
- The phase three RCT demonstrated the efficacy of baricitinib in children with atopic dermatitis, particularly at the 4 mg dose, showing favorable outcomes without significant safety concerns.
- A systematic review of Janus kinase inhibitors in atopic dermatitis found no substantial increase in major adverse cardiovascular events, indicating the need for further real-world studies to confirm these findings.
- Anifrolumab showed promising results in therapy-resistant cutaneous lupus, indicating potential for personalized treatment approaches.
- Baricitinib demonstrated variable response times in alopecia areata patients, suggesting the importance of managing expectations based on baseline severity rather than disease duration.
- Individuals perceived as younger based on facial appearance had lower rates of age-related diseases, highlighting a psychological connection between perceived and actual health outcomes.
- Real-world data supports that adalimumab is more effective than methotrexate in treating psoriasis, with increased treatment adherence in patients.
- Metformin's mechanism in hidradenitis suppurativa involves suppressing the NLRP3 inflammasome, providing a biochemical rationale for its effectiveness in treating the condition.
- Innovative approaches in global skin health revealed significant improvements in treatment outcomes for lymphatic filariasis using integrative methods like Ayuredic practices and compression therapy.
- Establishing core outcome measures for atopic dermatitis could enhance comparative effectiveness research across different treatment modalities.
- The graphical abstracts facilitate comprehension and dissemination of complex treatment studies, enhancing clinical application.
- NCT02576938
- NCT02925117
- NCT02780167
- NCT04162899
- BJD British Journal of Dermatology